RXFP1 효능제로서의 벤조티오펜 유도체

• Main Authors: PINTO DONALD J. P, KUMAR SREEKANTHA RATNA, SMITH II LEON M, PASUNOORI LAXMAN, ORWAT MICHAEL J, SRINIVAS PITANI VEERA VENKATA, DURAISAMY SRINIVASAN KUNCHITHAPTHAM, HEGDE SUBRAMANYA, BARRE DURGA BUCHI RAJU, BHOGADI VIKRAM
• Format: Patent
• Language: Korean
• Published: 13.08.2024
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

본 개시내용은 RXFP1 효능제인 화학식 (I)의 화합물, 그를 함유하는 조성물, 및 예를 들어 심부전, 섬유화 질환 및 관련 질환, 예컨대 폐 질환 (예를 들어, 특발성 폐 섬유증), 신장 질환 (예를 들어, 만성 신장 질환) 또는 간 질환 (예를 들어, 비-알콜성 지방간염 및 문맥 고혈압)의 치료에서의 그의 사용 방법에 관한 것이다. 가변기 X1, X2, R1, R2, 및 R4는 본 개시내용에 정의된 바와 같다. TIFFpct00183.tif3436 The disclosure relates to compounds of Formula (I), which are RXFP1 agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension). Variables X1, X2, R1, R2, and R4 are as defined in the disclosure.